Synapse - Gregory Riely

Results (9)

Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas

Journal Article

Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
Clinical Cancer Research (2023)

Fulltext@MSK | Save

Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor

Journal Article

Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
JCO Precision Oncology (2021)

Fulltext@MSK | Save

Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial

Journal Article

Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
JAMA Oncology (2020)

Fulltext@MSK | Save

A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers

Meeting Abstract

Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases